Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Karyopharm Therapeutics
Biotech
Biogen takes nuclear option, terminating Karyopharm ALS pact
Biogen is jettisoning one of its three clinical-phase ALS assets, kicking an oral nuclear export inhibitor back to Karyopharm to narrow its focus.
Nick Paul Taylor
Jun 16, 2022 8:25am
John Mascola moves on from NIAID's R&D hub—Chutes and Ladders
Apr 1, 2022 9:30am
Karyopharm snags former Merck exec as chief medical officer
Mar 29, 2022 2:34pm
New discoveries in immuno-oncology and diabetes—News of note
Dec 9, 2019 11:00am
Testing Karyopharm's new multiple myeloma drug in glioblastoma
Jul 15, 2019 9:27am
FDA delays Karyopharm PDUFA to review extra information
Mar 15, 2019 9:35am
